Suppr超能文献

扎斯塔拉唑的体外代谢和转运特性

In Vitro Metabolism and Transport Characteristics of Zastaprazan.

作者信息

Lee Min Seo, Lee Jihoon, Pang Minyoung, Kim John, Cha Hyunju, Cheon Banyoon, Choi Min-Koo, Song Im-Sook, Lee Hye Suk

机构信息

College of Pharmacy and BK21 Four-Sponsored Advanced Program for SmartPharma Leaders, The Catholic University of Korea, Bucheon 14662, Republic of Korea.

BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Vessel-Organ Interaction Research Center (VOICE), Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.

出版信息

Pharmaceutics. 2024 Jun 13;16(6):799. doi: 10.3390/pharmaceutics16060799.

Abstract

Zastaprazan (JP-1366), a novel potassium-competitive acid blocker, is a new drug for the treatment of erosive esophagitis. JP-1366 is highly metabolized in human, mouse, and dog hepatocytes but moderately metabolized in rat and monkey hepatocytes when estimated from the metabolic stability of this compound in hepatocyte suspension and when 18 phase I metabolites and 5 phase II metabolites [i.e., -dearylation (M6), hydroxylation (M1, M19, M21), dihydroxylation (M7, M8, M14, M22), trihydroxylation (M13, M18), hydroxylation and reduction (M20), dihydroxylation and reduction (M9, M16), hydrolysis (M23), hydroxylation and glucuronidation (M11, M15), hydroxylation and sulfation (M17), dihydroxylation and sulfation (M10, M12), -dearylation and hydroxylation (M3, M4), -dearylation and dihydroxylation (M5), and -dearylation and trihydroxylation (M2)] were identified from JP-1366 incubation with the hepatocytes from humans, mice, rats, dogs, and monkeys. Based on the cytochrome P450 (CYP) screening test and immune-inhibition analysis with CYP antibodies, CYP3A4 and CYP3A5 played major roles in the metabolism of JP-1366 to M1, M3, M4, M6, M8, M9, M13, M14, M16, M18, M19, M21, and M22. CYP1A2, 2C8, 2C9, 2C19, and 2D6 played minor roles in the metabolism of JP-1366. UDP-glucuronosyltransferase (UGT) 2B7 and UGT2B17 were responsible for the glucuronidation of M1 to M15. However, JP-1366 and active metabolite M1 were not substrates for drug transporters such as organic cation transporter (OCT) 1/2, organic anion transporter (OAT) 1/3, organic anion transporting polypeptide (OATP)1B1/1B3, multidrug and toxic compound extrusion (MATE)1/2K, P-glycoprotein (P-gp), and breast cancer-resistant protein (BCRP). Only M1 showed substrate specificity for P-gp. The findings indicated that drug-metabolizing enzymes, particularly CYP3A4/3A5, may have a significant role in determining the pharmacokinetics of zastaprazan while drug transporters may only have a small impact on the absorption, distribution, and excretion of this compound.

摘要

扎斯塔普拉赞(JP - 1366)是一种新型钾离子竞争性酸阻滞剂,是治疗糜烂性食管炎的新药。根据该化合物在肝细胞悬液中的代谢稳定性估计,以及在人、小鼠、大鼠、犬和猴的肝细胞与JP - 1366孵育后鉴定出18种I相代谢物和5种II相代谢物[即去芳基化(M6)、羟基化(M1、M19、M21)、二羟基化(M7、M8、M14、M22)、三羟基化(M13、M18)、羟基化和还原(M20)、二羟基化和还原(M9、M16)、水解(M23)、羟基化和葡萄糖醛酸化(M11、M15)、羟基化和硫酸化(M17)、二羟基化和硫酸化(M10、M12)、去芳基化和羟基化(M3、M4)、去芳基化和二羟基化(M5)、去芳基化和三羟基化(M2)],JP - 1366在人、小鼠和犬的肝细胞中高度代谢,但在大鼠和猴的肝细胞中代谢程度中等。基于细胞色素P450(CYP)筛选试验和CYP抗体免疫抑制分析,CYP3A4和CYP3A5在JP - 1366代谢为M1、M3、M4、M6、M8、M9、M13、M14、M16、M18、M19、M21和M22的过程中起主要作用。CYP1A2、2C8、2C9、2C19和2D6在JP - 1366的代谢中起次要作用。尿苷二磷酸葡萄糖醛酸基转移酶(UGT)2B7和UGT2B17负责M1至M15的葡萄糖醛酸化。然而,JP - 1366和活性代谢物M1不是有机阳离子转运体(OCT)1/2、有机阴离子转运体(OAT)1/3、有机阴离子转运多肽(OATP)1B1/1B3、多药和有毒化合物外排(MATE)1/2K、P - 糖蛋白(P - gp)和乳腺癌耐药蛋白(BCRP)等药物转运体的底物。只有M1对P - gp表现出底物特异性。这些发现表明,药物代谢酶,特别是CYP3A4/3A5,可能在决定扎斯塔普拉赞的药代动力学方面起重要作用,而药物转运体可能对该化合物的吸收、分布和排泄影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a61d/11207335/3a0d43a083cc/pharmaceutics-16-00799-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验